Effects of intracavitary administration of elemene combined with nedaplatin on malignant pleural effusion.

Autor:	Chen KH; Chongqing Red Cross Hospital, People's Hospital of Jiangbei District, Department of Tumor and Hematology, 400020 Chongqing, China., Yang YS; Chongqing Red Cross Hospital, People's Hospital of Jiangbei District, Department of Tumor and Hematology, 400020 Chongqing, China. Electronic address: yangys6033@sina.com., Chen R; Chongqing Red Cross Hospital, People's Hospital of Jiangbei District, Department of Tumor and Hematology, 400020 Chongqing, China., Ning Z; Fusheng Community Health Service Center, 401133 Chongqing, China., Zhang CY; Chongqing Red Cross Hospital, People's Hospital of Jiangbei District, Department of Tumor and Hematology, 400020 Chongqing, China., Yu HY; Chongqing Red Cross Hospital, People's Hospital of Jiangbei District, Department of Tumor and Hematology, 400020 Chongqing, China., Ou XM; Chongqing Red Cross Hospital, People's Hospital of Jiangbei District, Department of Tumor and Hematology, 400020 Chongqing, China.
Jazyk:	angličtina
Zdroj:	Bulletin du cancer [Bull Cancer] 2022 Jun; Vol. 109 (6), pp. 642-647. Date of Electronic Publication: 2021 Oct 14.
DOI:	10.1016/j.bulcan.2021.06.014
Abstrakt:	Aim: To investigate the therapeutic effect of Elemene combined with Nedaplatin (ECN) on malignant pleural effusion (MPE) and its adverse reactions. Method: A retrospective study was conducted, three hundred and fifty-two patients with MPE were divided into two groups according to different treatment methods. One hundred and eighty-nine patients were given intrathoracic injection of ECN and classified in ECN group; one hundred and sixty-three cases in the Nedaplatin group were given intrathoracic injection of nedaplatin. Routine treatments were used to prevent adverse reactions. Result: The effective rate of the ECN group was 57.05%, and that of the Nedaplatin group was 23.08%. The comparison results of adverse reactions between the two groups showed that there was no significant difference in leukopenia, thrombopenia, anemia, vomitting and diarrhea, fever, hepatic damage and renal damage. The level of thoracalgia in the ECN group was higher than that in the Nedaplatin group. There was no significant change in the number of CD8+ T cells between the two groups after treatment. The number of CD4+T cells in the ECN group increased after treatment was higher than the Nedaplatin group after treatment. Conclusion: ECN treatment can improve clinical control of MPE with no serious adverse reaction, can effectively reduce the immunosuppressive effect of nedaplatin and enhance the immune function of MPE patients which is worthy of clinical application. (Copyright © 2021. Published by Elsevier Masson SAS.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu